INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered
View HTML
Toggle Summary NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage
View HTML
Toggle Summary NantKwest Names Angela Wilson Chief Financial Officer
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 17, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the
View HTML
Toggle Summary NantKwest Names Sonja Nelson Chief Financial Officer
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 19, 2018-- NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson , chief accounting officer for the company, to the role of Chief Financial Officer (CFO). This press release features multimedia.
View HTML
Toggle Summary NantKwest Provides Update on Clinical Programs at Bank of America Healthcare Conference Multiple Immunotherapy Combinations Announced as Part of Cancer Moonshot 2020 Initiative
CULVER CITY, Calif. --(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2019-- NantKwest, Inc. (Nasdaq:NK) , a leading clinical-stage Natural Killer (NK)
View HTML
Toggle Summary NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 19, 2016-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 5, 2018-- NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, announced today that the company will
View HTML
Toggle Summary NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 5, 2019-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest to Host Investor Day on January 14, 2016
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, announced today that
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.